Spravato (Esketamine) in Gilbert

Spravato is esketamine — a nasal-spray form of one half of the ketamine molecule, FDA-approved for treatment-resistant depression and for depressive symptoms with acute suicidal thinking or behavior, taken alongside an oral antidepressant.

Two things separate it from the take-home ketamine program we already offer. First, the approval: because Spravato is FDA-approved for depression, insurance typically covers it — often the deciding factor when a self-pay program is out of reach. Second, the setting: Spravato can only be given in a certified healthcare setting under a federal safety program (REMS), with a required two-hour observation after each dose. Some patients prefer that fully in-office structure; others are better served by the evaluated, trial-assessed take-home program. That is exactly the kind of fit question the evaluation answers.

We are building toward offering Spravato at the Gilbert office inside LifeSpann. Certification and insurance contracting come first, and we will not take bookings until both are real. In the meantime, take-home ketamine therapy is available now for patients who are candidates, and the evaluation is the same starting point for either path.